Genprex (NASDAQ:GNPX) Sees Large Volume Increase

Shares of Genprex Inc (NASDAQ:GNPX) saw unusually-high trading volume on Tuesday . Approximately 11,638,100 shares traded hands during mid-day trading, an increase of 11,036% from the previous session’s volume of 104,505 shares.The stock last traded at $0.62 and had previously closed at $0.39.

Separately, ValuEngine upgraded shares of Genprex from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

The firm has a market cap of $6.38 million, a P/E ratio of -0.69 and a beta of 1.36. The firm’s fifty day moving average is $0.53 and its two-hundred day moving average is $1.03.

A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC acquired a new stake in shares of Genprex Inc (NASDAQ:GNPX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned 0.20% of Genprex at the end of the most recent quarter. 12.86% of the stock is owned by hedge funds and other institutional investors.

About Genprex (NASDAQ:GNPX)

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

See Also: What is a Candlestick Chart?

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.